Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current development of CFTR potentiators in the last decade.

European journal of medicinal chemistry - 15 Oct 2020

Spanò Virginia, Venturini Arianna, Genovese Michele, Barreca Marilia, Raimondi Maria Valeria, Montalbano Alessandra, Galietta Luis J V, Barraja Paola

Abstract excerpt

Cystic fibrosis (CF) is a genetic disorder produced by the loss of function of CFTR, a main chloride channel involved in transepithelial salt and water transport. CFTR function can be rescued by small molecules called "potentiators" which increase gating activity of CFTR on epithelial surfaces. High throughput screening (HTS) assays allowed the identification of new chemical entities endowed with potentiator...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycine

Share to Mutation

Share to Quinolones

Share to Small Molecule Libraries

Share to Structure-Activity Relationship

Share to Triazoles

Source

Identifiers

PMID: 32898816
DOI: 10.1016/j.ejmech.2020.112631

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current development of CFTR potentiators in the last decade.PMID 32898816Read ↗

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.Semantic proximity Read ↗

Discovery of CFTR modulators for the treatment of cystic fibrosis.Semantic proximity Read ↗

Structure-based discovery of CFTR potentiators and inhibitorsSemantic proximity Read ↗

Ion Channel Modulators in Cystic Fibrosis.Semantic proximity Read ↗

Toward inclusive therapy with CFTR modulators: Progress and challengesSemantic proximity Read ↗

Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent.Semantic proximity Read ↗

CFTR pharmacology.Semantic proximity Read ↗

Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.Semantic proximity Read ↗

Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic FibrosisSemantic proximity Read ↗

Small-molecule drugs for cystic fibrosis: Where are we now?Semantic proximity Read ↗

New drugs in cystic fibrosis: what has changed in the last decade?Semantic proximity Read ↗

A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.